NIKKEI 225
38,432.38 -402.72 (-1.04%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.25 -0.13 (-0.17%) GOLD FUTURES
2,322.10 -2.10 (-0.09%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
50,103.45 -697.49 (-1.37%)
MRK Oct 2024 140.000 call
| Previous close | 2.7100 |
| Open | 2.4300 |
| Bid | 3.0500 |
| Ask | 3.2000 |
| Strike | 140.00 |
| Expiry date | 2024-10-18 |
| Day's range | 2.4300 - 3.1300 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.42k |
Simply Wall St.Merck First Quarter 2024 Earnings: Beats Expectations
Merck ( NYSE:MRK ) First Quarter 2024 Results Key Financial Results Revenue: US$15.8b (up 8.9% from 1Q 2023). Net...
ZacksHere's Why Merck (MRK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BenzingaMerck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after ending 2023 with good news from its combined treatment with Moderna Inc (NASDAQ: MRNA) in fighting melanoma. Merck reported improvement in cancer patients receiving its Keytruda regimen. Enrolling 698 subjects, the trial evaluated the effect of a treatment that combines Merck’s immunotherapy blockb
